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Cystic fibrosis related diabetes (CFRD) is an important complication of CF that increases mortality. Adiponectin, an adipokine secreted from
adipose tissue, plays an important role in fatty acid and glucose metabolism. Lower total adiponectin (TA) levels have been linked to the risk of
developing type 2 diabetes. However, studies show that the high molecular weight isoform (HMW), thought to be more active than TA, might be a
better indicator of insulin sensitivity.
Our aim was to determine the association between HMW and insulin sensitivity in CF subjects and determine if other factors might modulate
its levels.
Thirteen control subjects and 47 CF adults (16 with normal glucose tolerance, 16 prediabetic and 15 with CFRD) underwent an oral glucose
tolerance test. Blood samples were taken at time 0, 30, 60, 90 and 120 min. Body mass index, fibrinogen, glucose and insulin, TA and HMW were
measured in every subject. Regression analysis was used to determine the association between TA, HMW and glucose (fasting glucose, 2 h
glucose and glucose AUC) as well as insulin (fasting insulin, insulin AUC, and Stumvoll insulin sensitivity index) parameters.
TA and HMW levels were similar between CF patients and controls and were not associated to insulin sensitivity. TA was negatively
associated to insulin AUC (p=0.0108) and 2 h glucose (p=0.0116) in controls while these relationships were either weakly negative (p=0.0208)
or weakly positive (p=0.0105) in CF patients. Also, HMW was negatively associated to insulin (p=0.00301) and glucose AUC (p=0.0546) in
controls whereas these associations were positive in CF patients (p=0.0388, p=0.0232 respectively).
In conclusion, our exploratory study on HMW adiponectin demonstrated similar levels of TA and HMW between CF patients and controls and
different relationships between forms of adiponectin to glucose metabolism and insulin in CF.
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Cystic fibrosis related diabetes (CFRD) is an increasingly
frequent complication of CF [1]. CFRD is mainly caused by a
decrease in insulin secretion and possibly insulin resistance⁎ Corresponding author at: IRCM, 110 Avenue des Pins Ouest, Montréal, Québec
E-mail address: remi.rabasa-lhoret@ircm.qc.ca (R. Rabasa-Lhoret).
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doi:10.1016/j.jcf.2011.07.005[1,2]. The development of CFRD is associated with an increase
in morbidity and mortality [3].
Adiponectin, circulating as a mixture of multimeric com-
plexes including the high molecular weight (HMW) isoform, is
an adipokine secreted from adipose tissue. Adiponectin plays an, Canada H2W 1R7. Tel.: +1 514 987 5762; fax: +1 514 987 5670.
d by Elsevier B.V. All rights reserved.
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[4,5]. Lower levels of total adiponectin (TA) have been
associated to the risk of developing for type 2 diabetes [6].
However, recent studies suggest the HMW isoform is the most
active form [5] and correlated better to insulin sensitivity (IS)
than TA [7].
Our laboratory previously reported that CF subjects did not
show alterations in TA levels despite inflammation and reduced
IS [8]. Since the HMW form may be a more pertinent biomarker
for IS, we hypothesized that its levels would be better indicator
of IS in CF patients. Thus, we evaluated TA and HMW levels
and investigated factors that might modulate their levels in CF.2. Subjects and methods
Thirteen healthy controls with normal glucose tolerance (NGT)
and 47 CF adults (16 with NGT, 16 with impaired glucose
tolerance (IGT), 15 with CFRD) of the Montreal CF Cohort
(MCFC) matched with controls for gender and age were included
in this study (Table 1). The protocol was approved by the Research
Ethics Committee of the Centre Hospitalier de l'Université de
Montréal (CHUM). Inclusion and exclusion criteria have been
previously described [2,8].2.1. Clinical parameters
Body mass index (BMI in kg/m2) was determined with an
electronic scale (Tanita Corporation, Arlington Heights, IL, USA)
and a standard wall stadiometer. Pancreatic insufficiency was
defined as current use of pancreatic enzyme supplementation.2.2. OGTT
After an overnight fast, all subjects ingested a solution of 75 g
of glucose. Blood samples were taken at 0, 30, 60, 90 and 120 min
to measure in duplicate plasma glucose using the glucose oxidase
method (Beckman Coulter, Fullerton, CA, USA) and insulin with
a radioimmunoassay (Milipore, St Charles, MO, USA). Glucose
tolerance was determined according to the criteria of the Canadian
Diabetes Association [9].Table 1
Physical and metabolic characteristics of control and CF subjects.
Control
(n=13)
CF (n=47)
NGT (n=16)
Gender (M/F) 7/6 8/8
Age (years) 25.3±4.48 22.9±4.67
BMI (kg/m²) 22.2±1.68 22.0±1.97
Fibrinogen (g/L) 2.33±0.30 2.83±0.39 ⁎
Pancreatic insufficiency 0% 81%
Data are expressed as mean±SD.
CF: cystic fibrosis, NGT: normal glucose tolerance, IGT: impaired glucose toleranc
index, NS: nonsignificant.
# Overall p.
⁎ pb0.05 vs controls.2.3. Biochemical dosages
Fasting plasma TA and HMWwere quantified in duplicate by
ELISA (ALPCO Diagnostics, Salem, NH, USA). Fibrinogen, an
inflammatory marker, was quantified using a nephelometric assay
(Beckman Coulter Canada Inc., Mississauga, ON, Canada).
2.4. Insulin sensitivity and secretion
The Stumvoll insulin sensitivity index was calculated as
follows [10]: 0.156− 0.0000459× Insulin120− 0.000321 ×
Insulin0−0.00541×Glycemia120. Insulin secretion was quanti-
fied using the insulin area under the curve (AUC) (GraphPad
Software Inc., La Jolla, CA, USA) [11].
2.5. Statistics
Data are expressed in mean±SD and percentages. Statistical
analysis was done with R (R 2.13.0). Using a Kolmogorov–
Smirnov test, we determined all variables were normally
distributed. A one-way ANOVA was used to compare means of
variables between groups and a Tukey post-hoc was performed
when significant differences were found. Multiple linear re-
gressionswere used to determine if any of the following predictors
were associated with TA and HMW levels: fasting glucose, 2 h
glucose, glucose and insulin AUC, fasting insulin and Stumvoll
index. The limited sample size prevented us from fitting all the
variables together so we fitted several models, each of which
included one of the predictor listed above, plus an indicator of CF
status and their interaction. AICs (Akaike Information Criterion)
were used to determine which of the models including either a
glucose or an insulin parameter had the best fit. Statistical
significance was accepted at p≤0.05.
3. Results
3.1. Characteristics of CF subjects
Fibrinogen was higher in all CF patients than in controls
(pb0.05). Pancreatic insufficiency was frequent, ranging from
81% to 100% in CF groups. TA and HMW levels among controls
and CF groups were similar (Table 1).p #
IGT (n=16) CFRD (n=15)
8/8 6/9 –
28.3±7.70 28.7±9.20 NS
21.7±2.47 19.9±2.28 NS
2.84±0.53 ⁎ 2.91±0.50 ⁎ b0.05
94% 100% –
e, CFRD: cystic fibrosis related diabetes, M: male, F: female, BMI: body mass
Table 3
Multiple linear regression analysis.
Models Dependant
variables
Independent
variables
β Coefficient R2 total p
1 HMW Insulin AUC −7.59E-04 0.0469 0.0301
Insulin AUC∗CF 7.62E-04 0.0388
2 HMW Glucose AUC −5.68E-03 0.06967 0.0546
E
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The mean fasting plasma glucose, 2 h glucose and glucose
AUC were significantly higher in CFRD patients compared to
controls (pb0.05). CF-IGT and CFRD patients showed lower
insulinAUC and insulin sensitivity compared to controls (pb0.05)
(Table 2).Glucose AUC∗CF 7.02 -03 0.0232
3 TA Insulin AUC −1.11E-03 0.0688 0.0108
Insulin AUC∗CF 1.06E-03 0.0208
4 TA 2 h glucose −1.31 0.0677 0.0116
2 h glucose∗CF 1.35 0.0105
Independent variables used for the models 1–4: Fasting glucose, 2 h glucose,
Glucose AUC, Fasting insulin, Insulin AUC, Stumvoll index.3.3. Multiple linear regression analysis
As shown in Table 3, the best fittedmodels for HMWwerewith
insulin and glucose AUC. As for TA, the best fitted models were
with insulinAUCand 2 hglucose.We found a negative association
between insulin AUC and TA in controls (βInsulinAUC=−1.11E-03,
p=0.0108) while we found weaker negative association in CF
patients (βInsulinAUC+βInsulinAUC∗CF=−1.11E-03+−1.06E-03=
−0.05E-04, p=−0.0208). We observed a negative association
between 2 h glucose and HMW for controls (β2hglucose=−1.31,
p=0.0116), whereas for CF patients, there was a much weaker
positive association (β2hglucose +β2hglucose ∗ CF =− 1.31+
1.35=0.04, p=0.0105). In controls, there was a negative
association between insulin AUC and HMW (βInsulinAUC=
−7.59E-04,p=0.00301) whereas in CF patients, there was a
positive association (βInsulinAUC+βInsulinAUC ∗CF=−7.59E-04+
7.62E-04=0.03E-04, p=−0.0388). For controls, there was a
negative association with HMW that was not significant
(βGlucoseAUC=−5.68E-03, p=0.0546) and in CF patients, the
association was positive (βGlucoseAUC+βGlucoseAUC∗CF=−5.68E-
03+7.02E-03=1.35E-03, p=0.0232).4. Discussion
In this study, we hypothesized that HMW would be a better
marker of IS in CF. Contrary to our hypothesis and extending
our previous report; we demonstrated that there was not an
association between HMW levels and IS. Also, HMW levels
were similar between CF patients and healthy controls.
However, associations between TA, HMW and parameters of
glucose and insulin metabolism are different in CF compared to
controls subjects.Table 2
Glucose and insulin values levels in controls and CF patients.
Control (n=13) CF (n=47)
NGT (n=16)
Fasting glucose (mmol/l) 4.95±0.44 5.15±0.54
2 h glucose (mmol/l) 5.04±1.22 5.50±0.93
Glucose AUC 698±169 930±109 ⁎
Fasting insulin (pmol/l) 12.3±4.05 10.8±3.65
Insulin AUC 6122±1453 5558±2499
Stumvoll index 0.0942±0.0143 0.0928±0.0202
HMW 2.66±1.59 2.94±1.51
TA 5.76±2.14 5.99±1.90
Data are expressed as mean±SD.
CF: cystic fibrosis, AUC: area under curve, NS: nonsignificant, HMW: high molecu
# Overall p.
⁎ pb0.05 vs controls.Using regression analysis, we observed that Insulin AUC was
negatively associated to both TA and HMW adiponectin in
controls. In vivo, hyperinsulinemic euglycemic clamps performed
in humans demonstrated that insulin suppresses adiponectin
expression [12]. However, this association was different in CF
patients. It was either weakly positive (HMW) or weakly negative
(TA) compared to controls. Studies in type 2 diabetes, have shown
that adiponectin is negatively associated to glycemia [13]. We
observed negative relationships betweenHMWand glucose AUC
as well as TA and 2 h glucose in control subjects. However, in CF
patients, those associations were positive. Therefore, it appears
that the relationship between glucose metabolism, insulin and
adiponectin (TA and HMW) is different in CF patients compared
to healthy counterparts.
CF is characterized by many conditions that could affect
adiponectin levels such as chronic energy deficiency secondary
to pancreatic insufficiency [14,15], frequent pulmonary in-
fections [14,16], increased oxidative stress [16,17], altered body
composition [18,19] and in some patients, liver disease [20,21],
glucose intolerance and/or insulin deficiency [2,22]. Some
factors might favor the increase of adiponectin in CF such as
reduced biliary route excretion [21], insulinopenia [22] and a
negative caloric balance [15] while others may favor its
reduction such as inflammation, oxidative stress [16] and
altered body composition [19]. The combination of all these
factors in large part related to the stage of the disease might
explain why TA and HMW are similar between CF patients andp #
IGT (n=16) CFRD (n=15)
5.23±0.94 6.19±1.01 ⁎ 0.001
8.68±0.56* 13.2±2.41 ⁎ 0.001
1149±151 ⁎ 1526±236 ⁎ 0.001
8.89±3.15 8.82±3.99 NS
3972±1274 ⁎ 3333±2123 ⁎ 0.001
0.0790±0.0886 ⁎ 0.0578±0.0150 ⁎ 0.001
3.28±2.14 3.36±1.78 NS
6.05±2.72 6.29±2.11 NS
lar weight, TA: total adiponectin.
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Moriconi et al. [24] found higher TA levels in more advanced
CF adults compared to healthy subjects.
In conclusion, our exploratory study on HMW adiponectin
demonstrated similar levels of TA and HMW between CF
patients and controls and different relationships between forms
of adiponectin to glucose metabolism and insulin. These
observations warrant further investigation of mechanisms
implicated in the regulation of TA and HMW in CF patients at
different stages of the disease.
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